Company intelligence / Profile preview

ZOE

London, England, United Kingdom

Ownership: Private
Employees: ~250
Development stage: Other

Overview

A large randomized controlled trial published in Nature Medicine in May 2024 demonstrated that personalized nutrition via the ZOE program improved cardiometabolic outcomes compared to standard dietary guidelines. Over seven years, more than sixty peer-reviewed papers have been published validating their approach. The company runs the world's largest in-depth nutrition study with over a hundred thousand participants.

Therapeutic areas: GastroenterologyMetabolic DisordersWomen's HealthEndocrinology
Modalities: Non-pharmacological therapyDeviceMicrobial therapy
Industry: Molecular Diagnostics

Partnerships

Academic partnerships with King's College London and Massachusetts General Hospital/Harvard Medical School for research studies.

Beyond the preview

Go deeper on ZOE.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ZOE.

Explore the full profile